Pharmacotherapy options for cluster headache. (June 2015)

• Record Type: Journal Article
• Authors: Obermann, Mark; Holle, Dagny; Naegel, Steffen; Burmeister, Jan; Diener, Hans-Christoph
• Is Part Of: Expert opinion on pharmacotherapy. Volume 16:Number 8(2015)
• Page Start: 1177
• Page End: 1184
• Publication Date: 2015-06
• Subjects: Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1517/14656566.2015.1040392
• Languages: English
• ISSNs: 1465-6566

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p> <italic> <bold>Introduction:</bold> </italic> Cluster headache (CH) is a primary headache disorder and the most common trigeminal autonomic cephalalgia. Patients suffer from very severe unilateral headache attacks accompanied by ipsilateral trigeminal autonomic symptoms. Previous studies described a high burden of disease due to its impact on social life as well as an increased suicide ideation rate. The mean time to diagnosis in western industrialized countries is estimated at 4 years.</p> <p> <bold> <italic>Areas covered:</italic> </bold> Many treatment options for CH exist, but due to the rarity of the disease, controlled randomized clinical studies remain difficult to perform. This review summarizes the current knowledge about the treatment of CH including internationally accepted treatment guidelines, and an additional MEDLINE search (1 February 2015).</p> <p> <bold> <italic>Expert opinion:</italic> </bold> International treatment recommendations and official guidelines give reassurance about specific pharmacotherapy options for CH, but only few of these are backed by sufficient scientific evidence. The limited therapeutic efficacy in some patients leads to the use of alternative, complementary, but also illicit drugs to better cope with the disease. Many single cases, case series and uncontrolled studies were performed with different substances in an attempt to find a better way to treat or prevent the excruciatingly painful attacks associated with CH. Large-scale, randomized controlled clinical trials are desperately needed in order to further increase the quality of patient care for this outstanding but terrifying disease.</p> </abstract>